Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Daniela Sia, Bojan Losic, Agrin Moeini, et al.
Nature Communications (2015) Vol. 6, Iss. 1
Open Access | Times Cited: 279

Showing 1-25 of 279 citing articles:

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1722
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Sumera I. Ilyas, Shahid A. Khan, Christopher L. Hallemeier, et al.
Nature Reviews Clinical Oncology (2017) Vol. 15, Iss. 2, pp. 95-111
Open Access | Times Cited: 1353
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesús M. Bañales, Vincenzo Cardinale, Guido Carpino, et al.
Nature Reviews Gastroenterology & Hepatology (2016) Vol. 13, Iss. 5, pp. 261-280
Open Access | Times Cited: 1123
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia, Augusto Villanueva, Scott L. Friedman, et al.
Gastroenterology (2016) Vol. 152, Iss. 4, pp. 745-761
Open Access | Times Cited: 1009
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 683
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Supriya K. Saha, Andrew X. Zhu, Charles S. Fuchs, et al.
The Oncologist (2016) Vol. 21, Iss. 5, pp. 594-599
Open Access | Times Cited: 668
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar, Siyuan Zheng, Marie‐Claude Gingras, et al.
Cell Reports (2017) Vol. 18, Iss. 11, pp. 2780-2794
Open Access | Times Cited: 538
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Ángela Lamarca, Lipika Goyal, et al.
Cancer Discovery (2017) Vol. 7, Iss. 9, pp. 943-962
Open Access | Times Cited: 528
Cholangiocarcinoma
Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 503
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, et al.
Cancer Discovery (2016) Vol. 7, Iss. 3, pp. 252-263
Open Access | Times Cited: 466
Cholangiocarcinoma: Current Knowledge and New Developments
Boris Blechacz
Gut and Liver (2016) Vol. 11, Iss. 1, pp. 13-26
Open Access | Times Cited: 440
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 1, pp. 3-15
Open Access | Times Cited: 342
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 2, pp. 165-171
Open Access | Times Cited: 328
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 321
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 320
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Ángela Lamarca, Jorge Barriuso, Mairéad G. McNamara, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 170-185
Open Access | Times Cited: 298
Functional and genetic deconstruction of the cellular origin in liver cancer
Jens U. Marquardt, Jesper B. Andersen, Snorri S. Thorgeirsson
Nature reviews. Cancer (2015) Vol. 15, Iss. 11, pp. 653-667
Closed Access | Times Cited: 290
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
Liangqing Dong, Dayun Lu, Ran Chen, et al.
Cancer Cell (2021) Vol. 40, Iss. 1, pp. 70-87.e15
Closed Access | Times Cited: 227
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Robert Montal, Daniela Sia, Carla Montironi, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 315-327
Open Access | Times Cited: 219
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini, Daniela Sia, Nabeel Bardeesy, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 2, pp. 291-300
Closed Access | Times Cited: 218
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar, Siyuan Zheng, Marie‐Claude Gingras, et al.
Cell Reports (2017) Vol. 19, Iss. 13, pp. 2878-2880
Open Access | Times Cited: 209
Human hepatic organoids for the analysis of human genetic diseases
Yuan Guan, Dan Xu, Phillip M. Garfin, et al.
JCI Insight (2017) Vol. 2, Iss. 17
Open Access | Times Cited: 196
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
Audra Boscoe, Catherine Rolland, Robin Kate Kelley
Journal of Gastrointestinal Oncology (2019) Vol. 10, Iss. 4, pp. 751-765
Open Access | Times Cited: 160
Page 1 - Next Page

Scroll to top